Doug Ingram

Fierce Pharma

Sarepta, despite key trial flop, will seek full nod for DMD meds

Sarepta’s Vyondys 53 and Amondys 45 failed to show a statistically significant difference versus placebo on a key measurement of DMD patient mobility.

Angus Liu Nov 4, 2025 7:56am

Sarepta shares rally on early successful DMD data

May 18, 2021 12:29pm

Sarepta trial unearths new side effects for DMD candidate

May 3, 2021 2:50pm